IVVD: 2311, a potent intramuscular COVID antibody, targets FDA submission by mid-2026 for broad access

PEMGARDA is currently available for COVID prevention in immunocompromised patients, while VYD2311, a next-generation intramuscular antibody with higher potency and broader access, is entering pivotal trials with a targeted FDA submission in mid-2026. Multipurpose antibody products for respiratory diseases are also being explored.

Based on Invivyd, Inc. [IVVD] Evercore ISI 8th Annual HealthCONx Conference Audio Transcript — Dec. 2 2025

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 20 through Nov. 26, 2025. Source: VerityData

Increases in Holdings

Staar Surgical (STAA)

Broadwood Partners raised its stake in the manufacturer of implantable eye lenses to 15,045,391 shares. Broadwood Partners did so through the purchase of 1.5 million Staar Surgical shares from Nov. 19 through Nov. 21 at per share prices ranging from $25.60 to $28.23. Following the latest purchases, Broadwood Partners owns 30.2% of Staar Surgical's outstanding stock. Shares of Staar Surgical have gained approximately 8.8% in value in 2025.

Gold Royalty (GROY)

Tether Holdings raised its stake in the gold-focused royalty company to 20,170,713 shares. Tether Holdings did so through the purchase of 11,870,713 Gold Royalty shares from Oct. 17 through Nov. 18 at per share prices ranging from $3.49 to $3.74. Following the latest purchases, Tether Holdings owns an 11.6% stake in Gold Royalty's outstanding stock. Shares of Gold Royalty have gained 208.9% in value in 2025.

Acadia Healthcare (ACHC)

Khrom Investments Fund increased its stake in the operator of behavioral healthcare facilities to 7,145,239 shares. Khrom Investments Fund did so through the purchase of 2,100,863 Acadia Healthcare shares from Oct. 10 through Nov. 24 at per share prices ranging from $14.38 to $24.37. Following the latest purchases, Khrom Investments Fund continues to own 7.7% of Acadia Healthcare's outstanding stock. Shares of Acadia have lost roughly 59.4% of their value in 2025

Butterfly Network (BFLY)

Glenview Capital Management increased its stake in the digital health business to 22,434,914 shares. Glenview Capital did so through the purchase of 2.8 million Butterfly Network shares from Nov. 19 through Nov. 21 at per share prices ranging from $2.01 to $2.65. Following the latest purchases, Glenview Capital Management continues to own 9.7% of Butterfly Network's outstanding stock. Shares of Butterfly Network have lost roughly 14.6% of their value in 2025.

Decreases in Holdings

National Energy Services Reunited (NESR)

Mubbadrah Investment reduced its stake in the integrated oilfield services provider to 5,146,010 shares. Mubbadrah did so through the sale of 1,515,464 National Energy Services shares from April 23 through Oct. 23 at per share prices ranging from $6.11 to $11.96. Following the latest sales, Mubbadrah Investment continues to own 5.1% of the company's outstanding stock. Shares have gained roughly 64% in value in 2025.

Invivyd (IVVD)

Adimab lowered its stake in the biopharmaceutical company to 20,454,490 shares. Adimab did so through the open market sale of 1,233,416 Invivyd shares on Nov. 17 at per share prices ranging from $3 to $3.05. Following the latest sales, Adimab continues to own 8.8% of Invivyd's outstanding stock. Shares of Invivyd have surged to gain 372.9% in value in 2025.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.